Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Leadership Transition
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Provides Vobramitamab Duocarmazine Update
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.